

WELLMARK FORMULARY CHANGES FOR JAN. 1, 2021

Wellmark and a statewide committee of pharmacists and physicians review the Wellmark Drug List several times a year. This review enables us to identify drugs that are the safest and most effective, while reducing costs and ensuring members have access to the drugs they need.

The chart below outlines the formulary changes effective Jan. 1, 2021.

Drug	Formulary Change/UM
Invokana®, Invokamet®, and Invokamet XR	MOVING FROM TIER 2/LEVEL 3 TO TIER 4/LEVEL 4. Adding medical necessity prior authorization (MN-PA). Farxiga, Jardiance, Xigduo XR, Synjardy, and Synjardy XR will be the preferred alternatives.
Brand ProAir® HFA	MOVING FROM TIER 1/LEVEL 2 TO TIER 4/LEVEL 4. Product selection penalty will apply based on benefit design. Generic will remain on Tier 1/Level 2.
Brand Proventil HFA and Ventolin HFA	MOVING FROM TIER 2 TO TIER 4 AND REMAIN ON LEVEL 4 (NO LEVEL CHANGE FOR BLUESIMPLICITYSM). Product selection penalty will apply based on benefit design. Generic will remain on Tier 1/Level 2.
ProAir RespiClick®	MOVING FROM TIER 1/LEVEL 2 TO TIER 4/LEVEL 4.
Dulera®	MOVING FROM TIER 2/LEVEL 2 TO TIER 4/LEVEL 4. Adding MN-PA. Advair, Breo Ellipta, and Symbicort (Brand only) will be the preferred alternatives.
Tymlos and Forteo®	MOVING FROM SPECIALTY PREFERRED (SP-P)/LEVEL 4 TO SPECIALTY NONPREFERRED (SP-NP)/LEVEL 5.
Trientine	MOVING FROM TIER 1 TO SP-P. No level change to BlueSimplicity.
Doxycycline Hyclate, 50mg tablets	MOVING FROM TIER 1/LEVEL 2 TO NOT COVERED. Doxycycline hyclate 50mg capsules and doxycycline monohydrate 50mg tablet/capsules will remain on Tier 1/Level 2.
Isosorbide Dinitrate, 40mg	MOVING FROM TIER 1/LEVEL 2 TO NOT COVERED. Isosorbide dinitrate 20mg tablets will remain on Tier 2/Level 2.
Mirvaso® and Rhofade®	ADDING QUANTITY LIMIT (1 [30 GM] TUBE/PUMP BOTTLE PER 30-DAY).
Trimso-San™ Gel	MOVING FROM TIER 4/LEVEL 4 TO NOT COVERED.
Nurtec™ and Reyvow®	CHANGING TO PREFERRED PRODUCTS AND MOVING FROM TIER 4 TO TIER 3.
Ubrelvy™	CHANGING TO NON-PREFERRED PRODUCT. No change to formulary placement.
Aimovig®	CHANGING TO PREFERRED in parallel with Ajoovy® and Emgality®.
Rybelsus®	MOVING FROM TIER 4/LEVEL 4 TO TIER 2/LEVEL 3.
Glyxambi® and Trijardy® XR	MOVING FROM TIER 4/LEVEL 4 TO TIER 2/LEVEL 3.
Contour Test Strips	CHANGING TO PREFERRED PRODUCT IN PARALLEL WITH ONETOUCH AND MOVING FROM TIER 3/LEVEL 4 TO TIER 2/LEVEL 3. Removing PA. Quantity limits and post-limit PA will remain in place.
Symbicort®	CHANGING TO PREFERRED PRODUCT AND MOVING FROM TIER 4/LEVEL 3 TO TIER 2/LEVEL 2. Removing MN-PA.
Farxiga®	CHANGING TO PREFERRED PRODUCT AND MOVING FROM TIER 4/LEVEL 4 TO TIER 2/LEVEL 2. Removing MN-PA.
Xigduo® XR	CHANGING TO PREFERRED PRODUCT AND MOVING FROM TIER 4/LEVEL 4 TO TIER 2/LEVEL 3. Removing MN-PA.

